<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang PH</submitter><funding>Ministry of Health and Welfare</funding><pagination>21367</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7721715</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>A significantly negative reversion in the QuantiFERON-TB Gold In-tube (QFT-GIT) test is reported in patients on dialysis, which makes the results unreliable. The CD4 and CD8 responses of the QFT-Gold plus (QFT-Plus) may have better positive consistency, but this needs to be investigated. We enrolled dialysis patients with baseline positive QFT-GIT&lt;sub>0&lt;/sub> results and conducted two rounds of follow-up paired QFT-GIT&lt;sub>1&amp;2&lt;/sub> and QFT-Plus&lt;sub>1&amp;2&lt;/sub> tests at an interval of 6 months. The positive consistency, concordance, and discordance of the QFT results were analyzed. A total of 236 patients on dialysis were screened, and 73 participants with positive QFT-GIT&lt;sub>0&lt;/sub> results were enrolled. The baseline QFT-GIT&lt;sub>0&lt;/sub> response was higher in the 1st QFT-Plus&lt;sub>1&lt;/sub>(</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis.</pubmed_title><pmcid>PMC7721715</pmcid><funding_grant_id>107-TDU-B-211-123002, 108-TDU-B-211-133002</funding_grant_id><pubmed_authors>Yu CJ</pubmed_authors><pubmed_authors>Shu CC</pubmed_authors><pubmed_authors>Wang PH</pubmed_authors><pubmed_authors>Lee CY</pubmed_authors><pubmed_authors>Wei YF</pubmed_authors><pubmed_authors>Lin SW</pubmed_authors><pubmed_authors>Lee SS</pubmed_authors><pubmed_authors>Wang JY</pubmed_authors><pubmed_authors>Lin SY</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis.</name><description>A significantly negative reversion in the QuantiFERON-TB Gold In-tube (QFT-GIT) test is reported in patients on dialysis, which makes the results unreliable. The CD4 and CD8 responses of the QFT-Gold plus (QFT-Plus) may have better positive consistency, but this needs to be investigated. We enrolled dialysis patients with baseline positive QFT-GIT&lt;sub>0&lt;/sub> results and conducted two rounds of follow-up paired QFT-GIT&lt;sub>1&amp;2&lt;/sub> and QFT-Plus&lt;sub>1&amp;2&lt;/sub> tests at an interval of 6 months. The positive consistency, concordance, and discordance of the QFT results were analyzed. A total of 236 patients on dialysis were screened, and 73 participants with positive QFT-GIT&lt;sub>0&lt;/sub> results were enrolled. The baseline QFT-GIT&lt;sub>0&lt;/sub> response was higher in the 1st QFT-Plus&lt;sub>1&lt;/sub>(</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-26T14:45:07.699Z</modification><creation>2025-04-06T14:40:47.73Z</creation></dates><accession>S-EPMC7721715</accession><cross_references><pubmed>33288814</pubmed><doi>10.1038/s41598-020-78374-3</doi></cross_references></HashMap>